Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension

Advances in Therapy

Volumn 20, Issue 3, 2003, Pages 149-163

  Netland, Peter A ^a   Robertson, Stella M ^b   Sullivan, E Kenneth ^b   Silver, Lewis ^b   Bergamini, Michael V W ^b   Krueger, Scott ^b   Weiner, Alan L ^b   Davis, Alberta A ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ALCON RESEARCH LTD   (United States)

Author keywords

Black; Latanoprost; Nonblack; Ocular hypertension; Open angle glaucoma; Timolol; Travoprost

Indexed keywords

LATANOPROST; TIMOLOL; TRAVOPROST;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA THICKNESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGRO; OPEN ANGLE GLAUCOMA; PROSPECTIVE STUDY; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STATISTICAL ANALYSIS;

EID: 0042527642     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850202     Document Type: Article

References (26)

1. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in East Baltimore. N Engl J Med. 1991;325:1412-1417.
2. Hiller R, Kahn HA. Blindness from glaucoma. Am J Ophthalmol. 1975;80:62-69.
3. Wilson R, Richardson TM, Hertzmark E, Grant WM. Race as a risk factor for progressive glaucomatous damage. Ann Ophthalmol. 1985;17:653-659.
4. Martin MJ, Sommer A, Gold EB, Diamond EL. Race and primary open-angle glaucoma. Am J Ophthalmol. 1985;99:383-387.
5. Leske MC, Connell AM, Wu SY, Hyman LG, Schachat AP. Risk factors for open-angle glaucoma. The Barbados Eye Study. Arch Ophthalmol. 1995;113:918-924.
6. Hellberg MR, Sallee VL, McLaughlin MA, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther. 2001;17:421-432.
7. Goldberg I, Cunha-Vaz J, Jacobsen JE, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001;10:414-422.
8. Robertson SM, Sullivan EK, Silver LH, et al. Differences between black and non-black patients with open-angle glaucoma or ocular hypertension in IOP-lowering response to travoprost. Invest Ophthalmol Vis Sci. 2001;42:S559. Abstract 3004.
9. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484.
10. Fellman RL, Sullivan EK, Ratliff M, et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology. 2002;109:998-1008.
11. Somova L, Mufunda J. Ethnic differences of renin-sodium profile and renal prostaglandins in the pathogenesis of systemic arterial hypertension. Cent Afr J Med. 1996;42:170-175.
12. LaRosa FA, Gross RL, Orengo-Nania S. Central corneal thickness of Caucasians and African Americans in glaucomatous and nonglaucomatous populations. Arch Ophthalmol. 2001;119:23-27.
13. Brandt JD, Beiser JA, Kass MA, Gordon MO. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology. 2001;108:1779-1788.
14. Katz IM, Berger ET. Effects of iris pigmentation on response of ocular pressure to timolol. Surv Ophthalmol. 1979;23:395-398.
15. Saliminen L, Imre G, Huupponen R. The effect of ocular pigmentation on intraocular pressure response to timolol. Acta Ophthalmol. 1985;63(suppl):15-18.
16. Netland PA, Schwartz B, Feke GT, Takamoto T, Konno S, Goger DG. Diversity of response of optic nerve head circulation to timolol maleate in gel-forming solution. J Glaucoma. 1999;8:164-171.
17. Wilensky JT, Gandhi N, Pan T. Racial influence in open angle glaucoma. Ann Ophthalmol. 1978; 10:1398-1402.
18. Grant WM, Burke JF. Why do some people go blind from glaucoma? Ophthalmology. 1982;89:991-998.
19. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of open-angle glaucoma. The Baltimore Eye Study. JAMA. 1991;266:369-374.
20. Wilson MR, Hertzmark E, Walker AM, Childs-Shaw K, Epstein DL. A case-control study of risk factors in open angle glaucoma. Arch Ophthalmol. 1987;105:1066-1071.
21. Schwartz AL, Love DC, Schwartz MA. Long-term follow-up of argon laser trabeculoplasty for uncontrolled open-angle glaucoma. Arch Ophthalmol. 1985;103:1482-1484.
22. Shingleton BJ, Distler JA, Baker BH. Filtration surgery in black patients. Early results in a West Indian population. Ophthalmic Surg. 1987;18:195-199.
23. Berson D, Zauberman H, Landau L. Filtering operation in Africans. Am J Ophthalmol. 1969;67:395-398.
24. Freedman J, Shen E, Aherens M. Trabeculectomy in a black American glaucoma population. Br J Ophthalmol. 1976;60:573-574.
25. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology. 1998;105:1146-1164.
26. Merrit JC, Perry OD, Ellison PS, et al. Effects of pilocarpine in blacks with open angle glaucoma. Glaucoma. 1985;7:127-130.